According to a new study published in The Journal of Clinical Endocrinology & Metabolism, preconception-initiated low-dose aspirin may help prevent pregnancy loss in women with high levels of C-reactive protein (CRP) who have previously lost a pregnancy.
Researchers from the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) reviewed original findings from the EAGeR (Effects of Aspirin in Gestation and Reproduction) trial. This study aimed to determine if daily low-dose aspirin could prevent subsequent pregnancy loss among women who experienced one or two prior losses.
For this analysis, study authors divided the women into three groups: low CRP (<0.70mg/L), mid CRP (0.70–<1.95mg/L) or high CRP (≥1.95mg/L). The women received either low-dose aspirin (81mg) daily or a placebo for up to six menstrual cycles where pregnancy was attempted and through 36 week’s gestation in those who conceived.
Researchers found no significant differences in birth rates between those receiving aspirin vs. placebo in both the low CRP and mid CRP groups. For women in the high CRP group, however, patients taking placebo had the lowest rate of live birth at 44% vs. patients taking aspirin who had a live birth rate of 59% (RR: 1.35, 95%CI: 1.08 to 1.67). Aspirin also seemed to decrease CRP levels in the high CRP group according to measurements at Week 8, 20, and 36 of pregnancy.
“In women attempting conception with elevated hsCRP and prior pregnancy loss, low-dose aspirin may increase clinical pregnancy and live birth rates,” concluded authors.
For more information visit academic.oup.com.